Immunotherapies in Thymic Malignancies

Prof. Heather A. Wakelee  speaks about the use of checkpoint inhibitors in Thymic Malignancies.

Will There Ever Be Progress for Leptomeningeal Carcinomatosis: An Update on the Multidisciplinary Management in the Setting of Immuno-Oncology and Precision Medicine

Highlights of prostate cancer research at ASCO2019

A randomized, placebo-controlled, phase III trial-in-progress to evaluate the efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma (ESCC)

Activity and safety of cabozantinib in patients with gastrointestinal stromal tumor after failure of imatinib and sunitinib: EORTC phase II trial 1317 CaboGIST.

To Infinity and Beyond: The Future of Immunotherapy in Gynecologic Malignancies

Hematologic Malignancies—Plasma Cell Dyscrasia

Sarcoma

ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS)

Targeting Breast Cancer: Breaking the Code

Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis.

Should Immunotherapy Change the Practice for Esophageal and Gastric Cancer in the Near Future?

Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update from CheckMate 275.

Identification of targetable molecular alterations in the NCI-COG Pediatric MATCH trial.

Highlights of the Metastatic Breast Cancer Session

Antiangiogenic and Targeted Therapies With or Without Anti-PD1/Anti-PD-L1